Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2021

Open Access 01-12-2021 | Type 2 Diabetes | Review

Variability of risk factors and diabetes complications

Authors: Antonio Ceriello, Francesco Prattichizzo

Published in: Cardiovascular Diabetology | Issue 1/2021

Login to get access

Abstract

Several studies suggest that, together with glucose variability, the variability of other risk factors, as blood pressure, plasma lipids, heart rate, body weight, and serum uric acid, might play a role in the development of diabetes complications. Moreover, the variability of each risk factor, when contemporarily present, may have additive effects. However, the question is whether variability is causal or a marker. Evidence shows that the quality of care and the attainment of the target impact on the variability of all risk factors. On the other hand, for some of them causality may be considered. Although specific studies are still lacking, it should be useful checking the variability of a risk factor, together with its magnitude out of the normal range, in clinical practice. This can lead to an improvement of the quality of care, which, in turn, could further hesitate in an improvement of risk factors variability.
Literature
1.
go back to reference Ceriello A, Monnier L, Owens D. Glycaemic variability in diabetes: clinical and therapeutic implications. Lancet Diabetes Endocrinol. 2019;7:221–30.PubMedCrossRef Ceriello A, Monnier L, Owens D. Glycaemic variability in diabetes: clinical and therapeutic implications. Lancet Diabetes Endocrinol. 2019;7:221–30.PubMedCrossRef
2.
go back to reference Ranjan AG, Rosenlund SV, Hansen TW, Rossing P, Andersen S, Nørgaard K. Improved time in range over 1 year is associated with reduced albuminuria in individuals with sensor-augmented insulin pump-treated type 1 diabetes. Diabetes Care. 2020;43(11):2882–5.PubMedCrossRef Ranjan AG, Rosenlund SV, Hansen TW, Rossing P, Andersen S, Nørgaard K. Improved time in range over 1 year is associated with reduced albuminuria in individuals with sensor-augmented insulin pump-treated type 1 diabetes. Diabetes Care. 2020;43(11):2882–5.PubMedCrossRef
3.
go back to reference Hirakawa Y, et al. Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial. Diabetes Care. 2014;37:2359–65.PubMedCrossRef Hirakawa Y, et al. Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial. Diabetes Care. 2014;37:2359–65.PubMedCrossRef
4.
go back to reference Zinman B, et al. Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). Diabetologia. 2018;61:48–57.PubMedCrossRef Zinman B, et al. Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). Diabetologia. 2018;61:48–57.PubMedCrossRef
5.
go back to reference Zhou JJ, Schwenke DC, Bahn G, Reaven P, VADT Investigators. Glycemic variation and cardiovascular risk in the Veterans Affairs Diabetes Trial. Diabetes Care. 2018;41:2187–94.PubMedPubMedCentralCrossRef Zhou JJ, Schwenke DC, Bahn G, Reaven P, VADT Investigators. Glycemic variation and cardiovascular risk in the Veterans Affairs Diabetes Trial. Diabetes Care. 2018;41:2187–94.PubMedPubMedCentralCrossRef
6.
go back to reference Echouffo-Tcheugui JB, Zhao S, Brock G, Matsouaka RA, Kline D, Joseph JJ. Visit-to-visit glycemic variability and risks of cardiovascular events and all-cause mortality: the ALLHAT study. Diabetes Care. 2019;42:486–93.PubMedPubMedCentralCrossRef Echouffo-Tcheugui JB, Zhao S, Brock G, Matsouaka RA, Kline D, Joseph JJ. Visit-to-visit glycemic variability and risks of cardiovascular events and all-cause mortality: the ALLHAT study. Diabetes Care. 2019;42:486–93.PubMedPubMedCentralCrossRef
7.
go back to reference Sheng CS, et al. Prognostic significance of long-term HbA1c variability for all-cause mortality in the ACCORD trial. Diabetes Care. 2020;43:1185–90.PubMedCrossRef Sheng CS, et al. Prognostic significance of long-term HbA1c variability for all-cause mortality in the ACCORD trial. Diabetes Care. 2020;43:1185–90.PubMedCrossRef
8.
go back to reference Ceriello A, Ofstad AP, Zwiener I, Kaspers S, George J, Nicolucci A. Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial. Cardiovasc Diabetol. 2020;19:176.PubMedPubMedCentralCrossRef Ceriello A, Ofstad AP, Zwiener I, Kaspers S, George J, Nicolucci A. Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial. Cardiovasc Diabetol. 2020;19:176.PubMedPubMedCentralCrossRef
9.
go back to reference Grove JS, Reed DM, Yano K, Hwang LJ. Variability in systolic blood pressure: a risk factor for coronary heart disease? Am J Epidemiol. 1997;145:771–6.PubMedCrossRef Grove JS, Reed DM, Yano K, Hwang LJ. Variability in systolic blood pressure: a risk factor for coronary heart disease? Am J Epidemiol. 1997;145:771–6.PubMedCrossRef
10.
go back to reference Hata J, ADVANCE Collaborative Group, et al. Effects of visit-to-visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial. Circulation. 2013;128:1325–34.PubMedCrossRef Hata J, ADVANCE Collaborative Group, et al. Effects of visit-to-visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial. Circulation. 2013;128:1325–34.PubMedCrossRef
11.
go back to reference Ohkuma T, ADVANCE Collaborative Group, et al. Prognostic value of variability in systolic blood pressure related to vascular events and premature death in type 2 diabetes mellitus: the ADVANCE-ON study. Hypertension. 2017;70:461–8.PubMedCrossRef Ohkuma T, ADVANCE Collaborative Group, et al. Prognostic value of variability in systolic blood pressure related to vascular events and premature death in type 2 diabetes mellitus: the ADVANCE-ON study. Hypertension. 2017;70:461–8.PubMedCrossRef
12.
go back to reference Wan EY, Fung CS, Yu EY, Fong DY, Chen JY, Lam CL. Association of visit-to-visit variability of systolic blood pressure with cardiovascular disease and mortality in primary care Chinese patients with type 2 diabetes: a retrospective population-based cohort study. Diabetes Care. 2017;40:270–9.PubMedCrossRef Wan EY, Fung CS, Yu EY, Fong DY, Chen JY, Lam CL. Association of visit-to-visit variability of systolic blood pressure with cardiovascular disease and mortality in primary care Chinese patients with type 2 diabetes: a retrospective population-based cohort study. Diabetes Care. 2017;40:270–9.PubMedCrossRef
13.
go back to reference Yu ZB, et al. Association of visit-to-visit variability of blood pressure with cardiovascular disease among type 2 diabetes mellitus patients: a cohort study. Diabetes Metab J. 2019;43:350–67.PubMedPubMedCentralCrossRef Yu ZB, et al. Association of visit-to-visit variability of blood pressure with cardiovascular disease among type 2 diabetes mellitus patients: a cohort study. Diabetes Metab J. 2019;43:350–67.PubMedPubMedCentralCrossRef
14.
go back to reference Cardoso CRL, Leite NC, Salles GF. Prognostic importance of visit-to-visit blood pressure variability for micro- and macrovascular outcomes in patients with type 2 diabetes: the Rio de Janeiro type 2 diabetes cohort study. Cardiovasc Diabetol. 2020;19:50.PubMedPubMedCentralCrossRef Cardoso CRL, Leite NC, Salles GF. Prognostic importance of visit-to-visit blood pressure variability for micro- and macrovascular outcomes in patients with type 2 diabetes: the Rio de Janeiro type 2 diabetes cohort study. Cardiovasc Diabetol. 2020;19:50.PubMedPubMedCentralCrossRef
15.
go back to reference Nuyujukian DS, Koska J, Bahn G, Reaven PD, Zhou JJ, VADT Investigators. Blood pressure variability and risk of heart failure in ACCORD and the VADT. Diabetes Care. 2020;43:1471–8.PubMedCrossRefPubMedCentral Nuyujukian DS, Koska J, Bahn G, Reaven PD, Zhou JJ, VADT Investigators. Blood pressure variability and risk of heart failure in ACCORD and the VADT. Diabetes Care. 2020;43:1471–8.PubMedCrossRefPubMedCentral
16.
go back to reference McMullan CJ, Lambers Heerspink HJ, Parving HH, Dwyer JP, Forman JP, de Zeeuw D. Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan diabetic nephropathy trial. Am J Kidney Dis. 2014;64:714–22.PubMedCrossRef McMullan CJ, Lambers Heerspink HJ, Parving HH, Dwyer JP, Forman JP, de Zeeuw D. Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan diabetic nephropathy trial. Am J Kidney Dis. 2014;64:714–22.PubMedCrossRef
17.
go back to reference Viazzi F, AMD-Annals Study Group, et al. Long-term blood pressure variability and development of chronic kidney disease in type 2 diabetes. J Hypertens. 2019;37:805–13.PubMedCrossRef Viazzi F, AMD-Annals Study Group, et al. Long-term blood pressure variability and development of chronic kidney disease in type 2 diabetes. J Hypertens. 2019;37:805–13.PubMedCrossRef
18.
go back to reference Viazzi F, AMD-Annals Study Group, et al. Long-term blood pressure variability, incidence of hypertension and changes in renal function in type 2 diabetes. J Hypertens. 2020;38:2279–86.PubMedCrossRef Viazzi F, AMD-Annals Study Group, et al. Long-term blood pressure variability, incidence of hypertension and changes in renal function in type 2 diabetes. J Hypertens. 2020;38:2279–86.PubMedCrossRef
19.
go back to reference Waters DD, et al. Visit-to-visit variability of lipid measurements as predictors of cardiovascular events. J Clin Lipidol. 2018;12:356–66.PubMedCrossRef Waters DD, et al. Visit-to-visit variability of lipid measurements as predictors of cardiovascular events. J Clin Lipidol. 2018;12:356–66.PubMedCrossRef
20.
go back to reference Hulse M, Gershberg H. Variability in blood cholesterol, triglycerides, free fatty acids, glucose and body weight in maturity-onset diabetics. Am J Med Sci. 1969;258:114–20.PubMedCrossRef Hulse M, Gershberg H. Variability in blood cholesterol, triglycerides, free fatty acids, glucose and body weight in maturity-onset diabetics. Am J Med Sci. 1969;258:114–20.PubMedCrossRef
21.
go back to reference Takenouchi A, et al. Visit-to-visit low-density lipoprotein cholesterol variability is an independent determinant of carotid intima-media thickness in patients with type 2 diabetes. J Clin Med Res. 2017;9:310–6.PubMedPubMedCentralCrossRef Takenouchi A, et al. Visit-to-visit low-density lipoprotein cholesterol variability is an independent determinant of carotid intima-media thickness in patients with type 2 diabetes. J Clin Med Res. 2017;9:310–6.PubMedPubMedCentralCrossRef
22.
go back to reference Hsu WH, et al. Greater low-density lipoprotein cholesterol variability increases the risk of cardiovascular events in patients with type 2 diabetes mellitus. Endocr Pract. 2019;25:918–25.PubMedCrossRef Hsu WH, et al. Greater low-density lipoprotein cholesterol variability increases the risk of cardiovascular events in patients with type 2 diabetes mellitus. Endocr Pract. 2019;25:918–25.PubMedCrossRef
23.
go back to reference Lee EY, et al. Effect of visit-to-visit LDL-, HDL-, and non-HDL-cholesterol variability on mortality and cardiovascular outcomes after percutaneous coronary intervention. Atherosclerosis. 2018;279:1–9.PubMedCrossRef Lee EY, et al. Effect of visit-to-visit LDL-, HDL-, and non-HDL-cholesterol variability on mortality and cardiovascular outcomes after percutaneous coronary intervention. Atherosclerosis. 2018;279:1–9.PubMedCrossRef
24.
go back to reference Chang YH, Chang DM, Lin KC, Hsieh CH, Lee YJ. High-density lipo-protein cholesterol and the risk of nephropathy in type 2 diabetic patients. Nutr Metab Cardiovasc Dis. 2013;23:751–7.PubMedCrossRef Chang YH, Chang DM, Lin KC, Hsieh CH, Lee YJ. High-density lipo-protein cholesterol and the risk of nephropathy in type 2 diabetic patients. Nutr Metab Cardiovasc Dis. 2013;23:751–7.PubMedCrossRef
25.
go back to reference Ceriello A, Genovese S. Atherogenicity of postprandial hyperglycemia and lipotoxicity. Rev Endocr Metab Disord. 2016;17:111–6.PubMedCrossRef Ceriello A, Genovese S. Atherogenicity of postprandial hyperglycemia and lipotoxicity. Rev Endocr Metab Disord. 2016;17:111–6.PubMedCrossRef
26.
go back to reference Tsuboi A, Takenouchi A, Kurata M, Fukuo K, Kazumi T. Postmeal triglyceridemia and variability of HbA1c and postmeal glycemia were predictors of annual decline in estimated glomerular filtration rate in type 2 diabetic patients with different stages of nephropathy. J Diabetes Metab Disord. 2017;16:1.PubMedPubMedCentralCrossRef Tsuboi A, Takenouchi A, Kurata M, Fukuo K, Kazumi T. Postmeal triglyceridemia and variability of HbA1c and postmeal glycemia were predictors of annual decline in estimated glomerular filtration rate in type 2 diabetic patients with different stages of nephropathy. J Diabetes Metab Disord. 2017;16:1.PubMedPubMedCentralCrossRef
27.
go back to reference Bardini G, Innocenti M, Rotella CM, Giannini S, Mannucci E. Variability of triglyceride levels and incidence of microalbuminuria in type 2 diabetes. J Clin Lipidol. 2016;10:109–15.PubMedCrossRef Bardini G, Innocenti M, Rotella CM, Giannini S, Mannucci E. Variability of triglyceride levels and incidence of microalbuminuria in type 2 diabetes. J Clin Lipidol. 2016;10:109–15.PubMedCrossRef
28.
go back to reference Lissner L, et al. Variability of body weight and health outcomes in the Framingham population. N Engl J Med. 1991;324:1839–44.PubMedCrossRef Lissner L, et al. Variability of body weight and health outcomes in the Framingham population. N Engl J Med. 1991;324:1839–44.PubMedCrossRef
29.
go back to reference Bangalore S, Fayyad R, DeMicco DA, Colhoun HM, Waters DD. Body weight variability and cardiovascular outcomes in patients with type 2 diabetes mellitus. Circ Cardiovasc Qual Outcomes. 2018;11:e004724.PubMedCrossRef Bangalore S, Fayyad R, DeMicco DA, Colhoun HM, Waters DD. Body weight variability and cardiovascular outcomes in patients with type 2 diabetes mellitus. Circ Cardiovasc Qual Outcomes. 2018;11:e004724.PubMedCrossRef
30.
go back to reference Yeboah P, Hsu FC, Bertoni AG, Yeboah J. Body Mass Index, change in weight, body weight variability and outcomes in type 2 diabetes mellitus (from the ACCORD trial). Am J Cardiol. 2019;123:576–81.PubMedCrossRef Yeboah P, Hsu FC, Bertoni AG, Yeboah J. Body Mass Index, change in weight, body weight variability and outcomes in type 2 diabetes mellitus (from the ACCORD trial). Am J Cardiol. 2019;123:576–81.PubMedCrossRef
31.
go back to reference Zoppini G, Verlato G, Targher G, Bonora E, Trombetta M, Muggeo M. Variability of body weight, pulse pressure and glycaemia strongly predict total mortality in elderly type 2 diabetic patients. The Verona diabetes study. Diabetes Metab Res Rev. 2008;24:624–8.PubMedCrossRef Zoppini G, Verlato G, Targher G, Bonora E, Trombetta M, Muggeo M. Variability of body weight, pulse pressure and glycaemia strongly predict total mortality in elderly type 2 diabetic patients. The Verona diabetes study. Diabetes Metab Res Rev. 2008;24:624–8.PubMedCrossRef
32.
go back to reference Viazzi F, et al. Natural history and risk factors for diabetic kidney disease in patients with T2D: lessons from the AMD-annals. J Nephrol. 2019;32:517–25.PubMedCrossRef Viazzi F, et al. Natural history and risk factors for diabetic kidney disease in patients with T2D: lessons from the AMD-annals. J Nephrol. 2019;32:517–25.PubMedCrossRef
33.
go back to reference Verma S. Association between uric acid levels and cardio-renal outcomes and death in patients with type 2 diabetes: a subanalysis of EMPA-REG OUTCOME. Diabetes Obes Metab. 2020;22:1207–14.PubMedPubMedCentralCrossRef Verma S. Association between uric acid levels and cardio-renal outcomes and death in patients with type 2 diabetes: a subanalysis of EMPA-REG OUTCOME. Diabetes Obes Metab. 2020;22:1207–14.PubMedPubMedCentralCrossRef
34.
go back to reference Grossman C, Grossman E, Goldbourt U. Uric acid variability at midlife as an independent predictor of coronary heart disease and all-cause mortality. PLoS ONE. 2019;14:e0220532.PubMedPubMedCentralCrossRef Grossman C, Grossman E, Goldbourt U. Uric acid variability at midlife as an independent predictor of coronary heart disease and all-cause mortality. PLoS ONE. 2019;14:e0220532.PubMedPubMedCentralCrossRef
35.
go back to reference Lim SS, et al. Association of variability in uric acid and future clinical outcomes of patient with coronary artery disease undergoing percutaneous coronary intervention. Atherosclerosis. 2020;297:40–6.PubMedCrossRef Lim SS, et al. Association of variability in uric acid and future clinical outcomes of patient with coronary artery disease undergoing percutaneous coronary intervention. Atherosclerosis. 2020;297:40–6.PubMedCrossRef
36.
go back to reference Ceriello A, AMD-Annals Study Group, et al. Variability in HbA1c, blood pressure, lipid parameters and serum uric acid, and risk of development of chronic kidney disease in type 2 diabetes. Diabetes Obes Metab. 2017;19:1570–8.PubMedCrossRef Ceriello A, AMD-Annals Study Group, et al. Variability in HbA1c, blood pressure, lipid parameters and serum uric acid, and risk of development of chronic kidney disease in type 2 diabetes. Diabetes Obes Metab. 2017;19:1570–8.PubMedCrossRef
37.
go back to reference Bonora E, et al. Relationship of uric acid concentration to cardiovascular risk factors in young men. Role of obesity and central fat distribution. The Verona young men atherosclerosis risk factors study. Int J Obes Relat Metab Disord. 1996;20(11):975–80.PubMed Bonora E, et al. Relationship of uric acid concentration to cardiovascular risk factors in young men. Role of obesity and central fat distribution. The Verona young men atherosclerosis risk factors study. Int J Obes Relat Metab Disord. 1996;20(11):975–80.PubMed
38.
go back to reference Proceedings of a consensus development conference on standardized measures in diabetic neuropathy. Summary and recommendations. Diabetes Care 1992;15:1104–1107. Proceedings of a consensus development conference on standardized measures in diabetic neuropathy. Summary and recommendations. Diabetes Care 1992;15:1104–1107.
39.
go back to reference Tsuji H, et al. Impact of reduced heart rate variability on risk for cardiac events: the Framingham heart study. Circulation. 1996;94:2850–5.PubMedCrossRef Tsuji H, et al. Impact of reduced heart rate variability on risk for cardiac events: the Framingham heart study. Circulation. 1996;94:2850–5.PubMedCrossRef
40.
go back to reference Coopmans C, et al. Both prediabetes and type 2 diabetes are associated with lower heart rate variability: the Maastricht study. Diabetes Care. 2020;43:1126–33.PubMedCrossRef Coopmans C, et al. Both prediabetes and type 2 diabetes are associated with lower heart rate variability: the Maastricht study. Diabetes Care. 2020;43:1126–33.PubMedCrossRef
41.
go back to reference Gottsäter A, Ahlgren AR, Taimour S, Sundkvist G. Decreased heart rate variability may predict the progression of carotid atherosclerosis in type 2 diabetes. Clin Auton Res. 2006;16:228–34.PubMedCrossRef Gottsäter A, Ahlgren AR, Taimour S, Sundkvist G. Decreased heart rate variability may predict the progression of carotid atherosclerosis in type 2 diabetes. Clin Auton Res. 2006;16:228–34.PubMedCrossRef
42.
go back to reference Rodrigues TC, Ehrlich J, Hunter CM, Kinney GL, Rewers M, Snell-Bergeon JK. Reduced heart rate variability predicts progression of coronary artery calcification in adults with type 1 diabetes and controls without diabetes. Diabetes Technol Ther. 2010;12:963–9.PubMedPubMedCentralCrossRef Rodrigues TC, Ehrlich J, Hunter CM, Kinney GL, Rewers M, Snell-Bergeon JK. Reduced heart rate variability predicts progression of coronary artery calcification in adults with type 1 diabetes and controls without diabetes. Diabetes Technol Ther. 2010;12:963–9.PubMedPubMedCentralCrossRef
43.
go back to reference Kataoka M, Ito C, Sasaki H, Yamane K, Kohno N. Low heart rate variability is a risk factor for sudden cardiac death in type 2 diabetes. Diabetes Res Clin Pract. 2004;64:51–8.PubMedCrossRef Kataoka M, Ito C, Sasaki H, Yamane K, Kohno N. Low heart rate variability is a risk factor for sudden cardiac death in type 2 diabetes. Diabetes Res Clin Pract. 2004;64:51–8.PubMedCrossRef
44.
go back to reference May O, Arildsen H. Long-term predictive power of heart rate variability on all-cause mortality in the diabetic population. Acta Diabetol. 2011;48:55–9.PubMedCrossRef May O, Arildsen H. Long-term predictive power of heart rate variability on all-cause mortality in the diabetic population. Acta Diabetol. 2011;48:55–9.PubMedCrossRef
45.
go back to reference Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham heart study and the epidemiology of cardiovascular disease: a historical perspective. Lancet. 2014;383:999–1008.PubMedCrossRef Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham heart study and the epidemiology of cardiovascular disease: a historical perspective. Lancet. 2014;383:999–1008.PubMedCrossRef
46.
go back to reference Kim MK, et al. Associations of variability in blood pressure, glucose and cholesterol concentrations, and body mass index with mortality and cardiovascular outcomes in the general population. Circulation. 2018;138:2627–3263.PubMedCrossRef Kim MK, et al. Associations of variability in blood pressure, glucose and cholesterol concentrations, and body mass index with mortality and cardiovascular outcomes in the general population. Circulation. 2018;138:2627–3263.PubMedCrossRef
47.
go back to reference Kim MK, et al. Effects of variability in blood pressure, glucose, and cholesterol concentrations, and body mass index on end-stage renal disease in the general population of Korea. J Clin Med. 2019;8:755.PubMedCentralCrossRef Kim MK, et al. Effects of variability in blood pressure, glucose, and cholesterol concentrations, and body mass index on end-stage renal disease in the general population of Korea. J Clin Med. 2019;8:755.PubMedCentralCrossRef
48.
go back to reference Wightman SS, Sainsbury CAR, Jones GC. Visit-to-visit HbA1c variability and systolic blood pressure (SBP) variability are significantly and additively associated with mortality in individuals with type 1 diabetes: an observational study. Diabetes Obes Metab. 2018;20:1014–7.PubMedCrossRef Wightman SS, Sainsbury CAR, Jones GC. Visit-to-visit HbA1c variability and systolic blood pressure (SBP) variability are significantly and additively associated with mortality in individuals with type 1 diabetes: an observational study. Diabetes Obes Metab. 2018;20:1014–7.PubMedCrossRef
49.
go back to reference Chen Y, Jia T, Yan X, Dai L. Blood glucose fluctuations in patients with coronary heart disease and diabetes mellitus correlates with heart rate variability: a retrospective analysis of 210 cases. Niger J Clin Pract. 2020;23:1194–200.PubMedCrossRef Chen Y, Jia T, Yan X, Dai L. Blood glucose fluctuations in patients with coronary heart disease and diabetes mellitus correlates with heart rate variability: a retrospective analysis of 210 cases. Niger J Clin Pract. 2020;23:1194–200.PubMedCrossRef
50.
go back to reference Di Flaviani A, et al. Impact of glycemic and blood pressure variability on surrogate measures of cardiovascular outcomes in type 2 diabetic patients. Diabetes Care. 2011;34:1605–9.PubMedPubMedCentralCrossRef Di Flaviani A, et al. Impact of glycemic and blood pressure variability on surrogate measures of cardiovascular outcomes in type 2 diabetic patients. Diabetes Care. 2011;34:1605–9.PubMedPubMedCentralCrossRef
51.
go back to reference Hashemi Madani N, Ismail-Beigi F, Khamseh ME, Malek M, Ebrahimi Valojerdi A. Predictive and explanatory factors of cardiovascular disease in people with adequately controlled type 2 diabetes. Eur J Prev Cardiol. 2017;24:1181–9.PubMedCrossRef Hashemi Madani N, Ismail-Beigi F, Khamseh ME, Malek M, Ebrahimi Valojerdi A. Predictive and explanatory factors of cardiovascular disease in people with adequately controlled type 2 diabetes. Eur J Prev Cardiol. 2017;24:1181–9.PubMedCrossRef
52.
go back to reference Ceriello A, AMD-Annals Study Group, et al. Overall quality of care predicts the variability of key risk factors for complications in type 2 diabetes: an observational, longitudinal retrospective study. Diabetes Care. 2019;42:514–9.PubMedCrossRef Ceriello A, AMD-Annals Study Group, et al. Overall quality of care predicts the variability of key risk factors for complications in type 2 diabetes: an observational, longitudinal retrospective study. Diabetes Care. 2019;42:514–9.PubMedCrossRef
53.
go back to reference Kitaoka K, et al. Association of ABC (HbA1c, blood pressure and LDL-cholesterol) goal achievement with visit-to-visit ABC variability and postprandial dysmetabolism in type 2 diabetic patients. Asia Pac J Clin Nutr. 2020;29:476–82.PubMed Kitaoka K, et al. Association of ABC (HbA1c, blood pressure and LDL-cholesterol) goal achievement with visit-to-visit ABC variability and postprandial dysmetabolism in type 2 diabetic patients. Asia Pac J Clin Nutr. 2020;29:476–82.PubMed
55.
go back to reference Reach G, Pechtner V, Gentilella R, Corcos A, Ceriello A. Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus. Diabetes Metab. 2017;43(6):501–11.PubMedCrossRef Reach G, Pechtner V, Gentilella R, Corcos A, Ceriello A. Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus. Diabetes Metab. 2017;43(6):501–11.PubMedCrossRef
56.
go back to reference Ceriello A. Glucose variability and diabetic complications: is it time to treat? Diabetes Care. 2020;43:1169–71.PubMedCrossRef Ceriello A. Glucose variability and diabetic complications: is it time to treat? Diabetes Care. 2020;43:1169–71.PubMedCrossRef
57.
go back to reference Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet. 2010;375:906–15.PubMedCrossRef Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet. 2010;375:906–15.PubMedCrossRef
58.
go back to reference Kario K, Ferdinand KC, O’Keefe JH. Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease. Prog Cardiovasc Dis. 2020;63:249–62.PubMedCrossRef Kario K, Ferdinand KC, O’Keefe JH. Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease. Prog Cardiovasc Dis. 2020;63:249–62.PubMedCrossRef
59.
go back to reference Mann DM, et al. A pilot study identifying statin nonadherence with visit-to-visit variability of low-density lipoprotein cholesterol. Am J Cardiol. 2013;15:1437–42.CrossRef Mann DM, et al. A pilot study identifying statin nonadherence with visit-to-visit variability of low-density lipoprotein cholesterol. Am J Cardiol. 2013;15:1437–42.CrossRef
60.
go back to reference Bangalore S, et al. Relation of variability of low-density lipoprotein cholesterol and blood pressure to events in patients with previous myocardial infarction from the IDEAL trial. Am J Cardiol. 2017;119:379–87.PubMedCrossRef Bangalore S, et al. Relation of variability of low-density lipoprotein cholesterol and blood pressure to events in patients with previous myocardial infarction from the IDEAL trial. Am J Cardiol. 2017;119:379–87.PubMedCrossRef
61.
go back to reference Sjoberg N, Brinkworth GD, Wycherley TP, Noakes M, Saint DA. Moderate weight loss improves heart rate variability in overweight and obese adults with type 2 diabetes. J Appl Physiol. 2011;110:1060–4.PubMedCrossRef Sjoberg N, Brinkworth GD, Wycherley TP, Noakes M, Saint DA. Moderate weight loss improves heart rate variability in overweight and obese adults with type 2 diabetes. J Appl Physiol. 2011;110:1060–4.PubMedCrossRef
62.
Metadata
Title
Variability of risk factors and diabetes complications
Authors
Antonio Ceriello
Francesco Prattichizzo
Publication date
01-12-2021
Publisher
BioMed Central
Keyword
Type 2 Diabetes
Published in
Cardiovascular Diabetology / Issue 1/2021
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-021-01289-4

Other articles of this Issue 1/2021

Cardiovascular Diabetology 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.